Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The company’s first product, a palatable anti-parasitic drug, made to taste like toffee, united Pfizer’s skills as ... and a series of high-profile failures of drugs in development, such ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter ... is generally consistent with the profile of abemaciclib and what has ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Yesterday, the company reported ... and mucosal healing, said Pfizer. The drugmaker said that the results suggest etrasimod could offer a "best-in-class" profile for UC, particularly as the ...